# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Central Nervous System Lymphoma, Primary

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 41-46 of 46 results.
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
Status: Not yet recruiting
Last Changed: Jul 29, 2020
First Received: Jun 25, 2020
Disease(s): Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary
Intervention(s): Lenalidomide, Ibrutinib
Locations: CHU Amiens, Amiens, France
CHU Angers, Angers, France
CHU Besançon, Besançon, France
Institut Bergonié, Bordeaux, France
CHU Caen, Caen, France
... and 21 other locations.
The Clinical Implications of Immune Checkpoint Pathways in PCNSL
Status: Recruiting
Last Changed: Nov 08, 2019
First Received: Nov 08, 2019
Disease(s): Lymphoma, B-Cell
Intervention(s): non-intervention
Locations: National Taiwan University Hospital, Taipei, Taiwan
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Recruiting
Last Changed: Jun 07, 2019
First Received: Apr 20, 2015
Disease(s): Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
Intervention(s): Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study
Locations: M D Anderson Cancer Center, Houston, Texas, United States
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Status: Recruiting
Last Changed: Jul 09, 2020
First Received: Jul 09, 2020
Disease(s): Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
Intervention(s): 19(T2)28z1xx CAR T cells
Locations: Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.
Status: Recruiting
Last Changed: Jun 11, 2020
First Received: Jul 18, 2017
Disease(s): Brain Tumor
Intervention(s): abemaciclib, abemaciclib
Locations: Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States
... and 4 other locations.
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Jun 22, 2020
First Received: Apr 02, 2018
Disease(s): Lymphoma, Non-Hodgkin
Intervention(s): JCAR017
Locations: Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Austria
Universitair Ziekenhuis Gent, Gent, Belgium
Helsinki University, Helsinki, Finland
CHRU-Hopital Claude Huriez, Lille, France
Hopital Saint Louis, Paris Cedex 10, France
... and 16 other locations.